Hoffmann-la Roche

This study tests a new drug called glofitamab against standard treatments for mantle cell lymphoma that has returned or not responded to prior therapy. About 182 adults will be randomly assigned to receive glofitamab alone or one of two standard drug combinations. The main goal i…

This study follows about 40 people with Type 3 von Willebrand disease, a severe bleeding disorder, who are already on regular preventive treatment. Researchers will track how many bleeding episodes occur and how the condition affects daily life over at least 24 weeks. The goal is…

This early-stage study tests a new drug, RO7673396, in people with advanced solid tumors that have a RAS mutation. The goal is to find a safe dose and see if the drug can shrink tumors when used alone or with other cancer treatments. About 405 participants will take part in two s…

This study tests a new medicine called Afimkibart (RO7790121) for people with moderate to severe eczema (atopic dermatitis). About 160 adults will receive either the drug or a placebo to see if it improves skin symptoms like redness and itching. The main goal is to measure at lea…

This study tests a new medicine called NXT007 for people with severe or moderate hemophilia A, a condition where blood doesn't clot properly. The trial includes adults, teens, and children, and aims to see if the drug is safe and helps control bleeding. Participants may have inhi…

This study tests an experimental drug called trontinemab in 800 people with early Alzheimer's (mild cognitive impairment to mild dementia). The goal is to see if it can slow down memory and thinking problems over 72 weeks. Participants will receive either the drug or a placebo, a…

This study tests a refillable eye implant (port delivery system) that slowly releases medication for wet age-related macular degeneration. The implant is refilled every 36 weeks instead of monthly eye injections. About 250 people who have already responded to standard treatment w…

This early-phase study tests a new medicine called RO7669330, given as an eye injection, for people with geographic atrophy (a form of advanced age-related macular degeneration that causes vision loss). The main goal is to check safety and tolerability in about 132 participants. …

This study provides ongoing access to experimental cancer treatments for people who were already in a Roche-sponsored trial and still need the drug. It includes about 100 participants and focuses on safety and continued therapy. The goal is to keep treating patients who have no o…

This study will follow about 1,000 people in China who are already receiving faricimab for diabetic macular edema, retinal vein occlusion, or wet age-related macular degeneration. Researchers will track vision changes and treatment patterns over one year to see how well the drug …

This study tests a new gene therapy called SPK-10001 for people with Huntington's disease. The treatment is given once directly into the brain. The goal is to see if it is safe and can slow down the disease. About 53 adults with early-stage Huntington's will take part.

This study is testing several different drug combinations for people with multiple myeloma, a type of blood cancer. About 200 participants will receive one or more treatments to see if they are safe and help control the disease. The goal is to find better ways to manage the cance…

This study is for adults with type 1 or type 2 diabetes who use insulin injections. It compares a new continuous glucose monitor (CGM) to standard finger-prick testing. The goal is to see if the CGM helps people spend more time with their blood sugar in a healthy range (70-180 mg…

This study tests an experimental drug called trontinemab in 800 people with early Alzheimer's (mild memory loss to mild dementia). The goal is to see if it can slow down the disease. Participants will receive either the drug or a placebo, and neither they nor their doctors will k…

This study tests a small implant placed in the eye that releases medication every 24 weeks, compared to standard monthly eye injections. It involves 68 Chinese patients with wet age-related macular degeneration who have already responded to treatment. The goal is to see if the im…

This study tests a new drug called RO7790121 (Afimkibart) in 425 people with moderate-to-severe Crohn's disease who haven't responded well to other treatments. Participants will receive either the drug or a placebo to see if it can reduce symptoms and heal the gut lining. The goa…

This study looks at the long-term safety and effectiveness of the drug afimkibart for people with atopic dermatitis (eczema). It is for adults who already took part in earlier afimkibart studies. Researchers will track side effects and measure how well the drug controls eczema ov…

This study tests a new medicine called sefaxersen in people with IgA nephropathy, a kidney disease that can lead to kidney failure. The drug works by blocking a part of the immune system that may cause kidney damage. About 428 adults who are at high risk of their kidney disease g…

This early-stage study tests an experimental oral drug, RO7795081, in 30 healthy Chinese adults who are overweight or have obesity. The main goal is to check the drug's safety and how the body processes it, not yet to prove weight loss. Participants are randomly assigned to recei…

This early-phase study tests a drug called inavolisib, alone or with immunotherapy, in people whose cancers have a specific PIK3CA gene change. About 30 adults with advanced head and neck or other solid tumors will take part. The goal is to see if the treatment is safe and shrink…

This study is testing several new combinations of immunotherapy drugs in people with advanced liver cancer that cannot be removed by surgery. The goal is to see if these combinations can shrink tumors or slow the disease. About 518 adults who have not had prior systemic treatment…

This study tests a drug called satralizumab in people with two rare autoimmune diseases that cause brain inflammation (NMDAR and LGI1 encephalitis). The goal is to see if the drug can improve disability and reduce the need for emergency treatments. About 152 adults will receive e…

This study tests a drug called alectinib in children and teens with ALK fusion-positive solid or brain tumors that have stopped responding to other treatments or have no standard options. The goal is to see if the drug is safe, how the body processes it, and whether it can shrink…

This study tests a drug called obinutuzumab in teens (12-17) and children (5-11) with active lupus nephritis, a serious kidney complication of lupus. The goal is to see if the drug can help the kidneys work better and reduce disease activity. Participants will receive either the …

This study aims to understand how the drug risdiplam works in the bodies of very young infants with spinal muscular atrophy (SMA). It will enroll up to 10 newborns under 20 days old to measure the drug's levels in their blood and check for safety. The goal is to gather informatio…

This study tests an experimental drug (RO7268489) added to standard treatment (ocrelizumab) in 360 adults with progressive multiple sclerosis. The goal is to see if it can delay worsening of disability, such as walking speed and hand function. Participants are randomly assigned t…

This study tests the drug ocrelizumab in 60 Chinese adults with relapsing or primary progressive multiple sclerosis (MS). The goal is to see how well it controls disease activity and reduces relapses over 48 weeks. Participants receive the drug by infusion, and researchers track …

This early-stage study tests a new drug called RO7812653 in 50 people with early Alzheimer's. The main goal is to check if the drug is safe and how the body processes it. Participants receive a single dose injected into the spine and are monitored closely for side effects. This r…

This study is checking the long-term safety of a small implant placed in the eye that slowly releases medicine to treat wet age-related macular degeneration, a common cause of vision loss in older adults. About 1,000 people who have already been in earlier studies will take part.…

This early-phase study tests two drugs, mosunetuzumab and venetoclax, for people with chronic lymphocytic leukemia (CLL) that has come back or stopped responding to treatment. The goal is to see if these drugs are safe and can shrink or control the cancer. About 137 adults will t…

This study observes 700 adults with lung or liver cancer who are already receiving atezolizumab as a shot under the skin. Researchers want to see how satisfied patients are with the injection process, how it affects their quality of life, and how well it works in everyday medical…

This study is a pre-screening program to identify people who may be eligible for future Alzheimer's treatment studies. It involves a blood test for a key Alzheimer's protein (pTau217) and a memory test. Up to 13,000 adults with memory concerns will participate, but no treatment i…

This early-stage study is testing a new drug called RO7806881 in 128 healthy adults to see if it is safe and how the body handles it. Participants receive either the drug or a placebo, and researchers monitor for side effects. The goal is to gather safety information before testi…

This study is observing 850 people with wet age-related macular degeneration or diabetic macular edema who are already receiving the drug faricimab. Researchers will track vision changes, treatment patterns, and safety over two years in routine clinic settings. The goal is to lea…

This study aims to understand why some breast cancers become resistant to treatment. Researchers will analyze tumor and blood samples from 320 people with different types of breast cancer. The goal is to find changes in the cancer that allow it to keep growing despite therapy. Th…

This study is an early test of a new medicine called RO7763505. It will check if the drug is safe and how the body processes it. The trial includes about 196 people, first healthy volunteers and then patients with stable coronary artery disease. Participants will receive either t…

This study is testing a new digital platform designed to help doctors and patients better monitor multiple sclerosis (MS). Researchers want to see if the platform is easy to use and if it improves care. About 500 people with relapsing-remitting MS will use a smartphone app, while…